Latest News and Press Releases

EXTON, PA, July 24, 2024 (GLOBE NEWSWIRE) -- Autoimmune hemolytic anemia (AIHA) encompasses a group of rare disorders characterized by the destruction of red blood cells due to autoantibodies. Among...

MINNEAPOLIS, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Aerobiology, part of the Pace® Analytical Services laboratory network, today announced that its Seattle, Washington, laboratory has achieved...

MINNEAPOLIS, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Aerobiology, part of the Pace® Analytical Services laboratory network, today announced that its Seattle, Washington, laboratory has achieved...

Falls Church, VA, April 16, 2020 (GLOBE NEWSWIRE) -- As the COVID-19 pandemic spreads across the globe, so does misinformation on personal protective equipment (PPE), decontamination and indoor air...

CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...

Falls Church (VA), April 16, 2019 (GLOBE NEWSWIRE) -- A groundbreaking hazard analysis formula showcased in the April 2019 issue of The Synergist, the magazine of the American Industrial Hygiene...

Apellis to receive up to $120 million in upfront and near-term milestone payments, with the potential for additional payments subject to mutual agreement Apellis retains exclusive worldwide...

CRESTWOOD, Ky., and WALTHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...

-  New data on APL-2 demonstrate improvements in hematological parameters in cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA) -  CAD patients treated with APL-2 had...

Treatment with APL-2 in eculizumab-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) resulted in broad control of hemolysis and normalization of mean hemoglobin to 12.2 g/dL by day 85, an...